June 29, 2022
Oyster Point Pharma Announces Operating Expense Streamlining Plan
Plan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of…
Pharmaceuticals, Biotechnology and Life Sciences
Plan to Continue to Drive TYRVAYA® Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of…
SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the…
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal…
– Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW…
COPENHAGEN, Denmark and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) — BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted…
SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating…
– Selection based on employee satisfaction and engagement –CLEVELAND, June 26, 2022 (GLOBE NEWSWIRE) — SPR Therapeutics has been awarded…
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will…
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is…
PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…